London, UK – March 09th, 2026 – Qinecsa, the global class leader in technology-powered pharmacovigilance solutions, has announced the release of HaloPV 6.2, the latest update to its pharmacovigilance platform designed to strengthen regulatory compliance, improve system stability, and support scalable multitenant operations for global safety teams.
The release introduces key enhancements across case intake and processing, aggregate reporting, terminology management, and regulatory submissions. HaloPV 6.2 helps pharmacovigilance organizations meet evolving global safety reporting requirements while improving operational performance and reliability across the platform.
Advancing Global Regulatory Readiness
HaloPV 6.2 introduces improvements designed to support regulatory readiness across global markets. The release ensures compliance with FDA E2B (R3) submission requirements ahead of the April 1 implementation deadline, enabling seamless electronic case transmission and uninterrupted regulatory reporting.
Enhancements to aggregate reporting workflows further improve the accuracy and consistency of PSUR, PBRER, and DSUR outputs, helping safety teams remain audit-ready while reducing manual reconciliation effort.
Enhancing Platform Reliability and Performance
The release also delivers targeted improvements to system performance and data integrity across core pharmacovigilance workflows, including case intake, case processing, and regulatory reporting.
Updates to terminology management introduce enhanced workflows aligned with MedDRA and WHO Drug Dictionary standards, improving consistency in product coding and reporting outputs across regions.
Additional platform refinements strengthen reliability across high-volume environments and support more efficient processing for organizations managing large safety data volumes.
Scaling Multitenant Pharmacovigilance Operations
HaloPV 6.2 further strengthens the platform’s multitenant SaaS capabilities, improving operational resilience and ensuring consistent performance across customer environments.
These enhancements enable organizations to deploy and scale pharmacovigilance operations more efficiently while maintaining strict regulatory compliance and data integrity standards.
Ensuring Compliance in Blinded Clinical Safety Reporting
The release also introduces updates that improve compliance in blinded clinical study processing. Enhanced controls reinforce data segregation and ensure appropriate handling of blinded and unblinded cases throughout the reporting lifecycle, reducing regulatory risk and strengthening submission accuracy.
Advancing the HaloPV Product Roadmap
HaloPV 6.2 represents an important step in Qinecsa’s broader product roadmap, which focuses on strengthening platform reliability, improving usability, and enabling scalable pharmacovigilance operations.
The next planned release, HaloPV 6.3, will introduce usability modernization, system performance improvements, and expanded audit log capabilities. Together, these enhancements establish a stronger operational foundation for the platform and support its continued evolution toward AI-driven safety automation capabilities.
Availability
HaloPV 6.2 is now available. Existing customers should contact their account representatives to plan upgrade and deployment schedules.
About Qinecsa
Qinecsa Solutions is a global pharmacovigilance specialist with more than 20 years’ experience supporting pharma, biotech, and public health organisations. The company combines scientific expertise with a flexible, technology-powered platform to solve complex safety challenges, reduce fragmentation, and help teams work with greater clarity and accountability.
Focused solely on drug safety, Qinecsa provides independent services and advanced PV solutions trusted by leading life sciences organisations and health authorities worldwide.
More at www.qinecsa.com
Media Contact:
Gemma Cholerton
Marketing Director
[email protected]